The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes

This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independ...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Win L., Bain, Steve C., Min, Thinzar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136364/
https://www.ncbi.nlm.nih.gov/pubmed/32185624
http://dx.doi.org/10.1007/s13300-020-00798-x
_version_ 1783518231927980032
author Yin, Win L.
Bain, Steve C.
Min, Thinzar
author_facet Yin, Win L.
Bain, Steve C.
Min, Thinzar
author_sort Yin, Win L.
collection PubMed
description This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independent risk factor for cardiovascular disease (CVD). GLP-1RAs are proven to be safe in terms of CVD, and some of them have been shown to have a beneficial effect on cardiovascular outcomes. The effect of GLP-1RAs on hard renal endpoints has yet to be established; to date, there have been no published GLP-1RA clinical trials with primary renal endpoints. In this review, we discuss the evidence for a renal protective role of GLP-1RAs, highlighting the secondary renal outcomes from recent cardiovascular outcome trials of this class of glucose-lowering therapies.
format Online
Article
Text
id pubmed-7136364
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-71363642020-04-09 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes Yin, Win L. Bain, Steve C. Min, Thinzar Diabetes Ther Review This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independent risk factor for cardiovascular disease (CVD). GLP-1RAs are proven to be safe in terms of CVD, and some of them have been shown to have a beneficial effect on cardiovascular outcomes. The effect of GLP-1RAs on hard renal endpoints has yet to be established; to date, there have been no published GLP-1RA clinical trials with primary renal endpoints. In this review, we discuss the evidence for a renal protective role of GLP-1RAs, highlighting the secondary renal outcomes from recent cardiovascular outcome trials of this class of glucose-lowering therapies. Springer Healthcare 2020-03-17 2020-04 /pmc/articles/PMC7136364/ /pubmed/32185624 http://dx.doi.org/10.1007/s13300-020-00798-x Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Yin, Win L.
Bain, Steve C.
Min, Thinzar
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
title The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
title_full The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
title_fullStr The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
title_full_unstemmed The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
title_short The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
title_sort effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136364/
https://www.ncbi.nlm.nih.gov/pubmed/32185624
http://dx.doi.org/10.1007/s13300-020-00798-x
work_keys_str_mv AT yinwinl theeffectofglucagonlikepeptide1receptoragonistsonrenaloutcomesintype2diabetes
AT bainstevec theeffectofglucagonlikepeptide1receptoragonistsonrenaloutcomesintype2diabetes
AT minthinzar theeffectofglucagonlikepeptide1receptoragonistsonrenaloutcomesintype2diabetes
AT yinwinl effectofglucagonlikepeptide1receptoragonistsonrenaloutcomesintype2diabetes
AT bainstevec effectofglucagonlikepeptide1receptoragonistsonrenaloutcomesintype2diabetes
AT minthinzar effectofglucagonlikepeptide1receptoragonistsonrenaloutcomesintype2diabetes

Ejemplares similares